ReviewCurrent opinion in virology2015
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.
Review in Current opinion in virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed.
- Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.The Journal of infectious diseases · 2024Trial
- Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.The Journal of infectious diseases · 2022Trial
- A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.The Journal of infectious diseases · 2022Trial
- Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.Nature communications · 2021Trial
- Article
- Structural vaccinology expedites rational design of next-generation vaccines for influenza and respiratory syncytial virus.Virologica Sinica · 2026Review
- Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice.Vaccines · 2026Article
- Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection.bioRxiv : the preprint server for biology · 2026Article
- Bivalent RSV prefusion F vaccination elicits effective neutralization of contemporary and monoclonal antibody-resistant RSV strains.NPJ vaccines · 2026Article
- Whole-Genome Phylodynamic Analysis of Respiratory Syncytial Virus-Maryland, USA, 2018-2024.Viruses · 2026Article
- Rational design 2.0: transitioning from static structural biology to computational prioritization and iterative vaccine optimization for RSV.Frontiers in immunology · 2026Review
- Genomic evolution and minority variant dynamics of RSV during the first season of nirsevimab implementation in Italy (2024-5).Virus evolution · 2026Article
- Venenum bufonis and its active constituents alleviate RSV-induced pneumonia in mice by suppressing macrophage infiltration and NLRP3 inflammasome activation.Virus research · 2026Article
- Review
- Epidemiological and phylogenetic characterization of human respiratory syncytial virus associated with severe acute respiratory infections in paediatric patients from 2016 to 2023 in Hangzhou, China.Microbial genomics · 2025Article
- Hydrophobic residue substitutions enhance the stability andJournal of virology · 2025Article
- Review
- A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion glycoprotein.Npj viruses · 2025Article
- Prevention of respiratory syncytial virus disease across the lifespan in Italy.Pneumonia (Nathan Qld.) · 2025Review
- Molecular Evolution of theMicroorganisms · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis, but despite decades of research a safe and effective vaccine has remained elusive. The viral fusion glycoprotein (RSV F) plays an obligatory role in the entry process and is the major target of neutralizing antibodies, making it an attractive target for vaccine development. This review will summarize the recently determined structures of RSV F in the prefusion and postfusion conformations and describe the location and properties of neutralizing epitopes on RSV F, including the newly identified prefusion-specific epitopes. The influence of these findings on vaccine development will also be discussed, with a focus on the rational design and optimization of vaccine antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.